UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 8-K


CURRENT REPORT


Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


August 7 , 2018

Date of Report (Date of earliest event reported)


Canbiola, Inc.

(Exact name of registrant as specified in its charter)


Florida


333-208293


20-3624118

(State or other jurisdiction of incorporation)


(Commission File Number)


(IRS Employer Identification No.)


960 South Broadway, Suite 120
Hicksville, NY

 

11801

(Address of principal executive offices)

 

(Zip Code)


Registrant ’ s telephone number, including area code: 516-205-4751



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

¨

Written communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


                                                                                                                Emerging growth company       X


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 






Item 8.01. Other Events


On August 7, 2018, Uptick Newswire issued a press release regarding its interview of the CEO and the Chief Medical Advisor for Canbiola, Inc. (the “ Company ” ) on its “ Stock Day ” podcast. Within the interview, the Company ’ s CEO, Marco Alfonsi, references a Press Release of the Company ’ s from July 9, 2018. Copies of both Uptick ’ s and the Company ’ s releases referenced above are included herewith as Exhibits.  


The information in the press releases and the Uptick interview are not to be deemed “ filed ” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits. The following exhibits are filed herewith.



Exhibit No.

 

Description

99.1


Uptick Press Release

99.2


Company Press Release







SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 

Canbiola, Inc.

 

 

 

 

 

Date: August 7, 2018

By:

/s/ Marco Alfonsi

Marco Alfonsi, CEO

 




 

 






Canbiola, Inc. (OTC PINK: CANB) Revenue and Shareholder 2nd Quarter Update

HICKSVILLE, NY., July 09, 2018 (GLOBE NEWSWIRE) -- Canbiola, Inc. (OTC PINK: CANB) Canbiola is pleased to update shareholders on our progress for the first half of 2018.

REVENUES:

We expect to have doubled our revenues in Q2 2018 as compared to Q1 2018; our Distribution and Outreach strategy appears to be beginning to take hold, and we are pleased with the progress and expect to continue this upward swing moving forward.

DISTRIBUTION:

The Company's commitment to penetrate the medical community will and always has been the foundation of our growth. This decision has made a very positive impact to our Private Physician Affiliate Program.  Our corporate sales to Functional and Alternative medical practices has grown.  Our nationwide Roll-Out has begun and continues to grow dramatically due to our strong affiliation with very clear-cut distribution channels. We see exponential growth to Doctors and Medical Practices nationwide selling Canbiola products. We have developed a new section on our site to help our potential clients locate doctors and practices in their locality. This feature can be found through our website at  https://canbiola.com/find-us-contact-us/ .

MANUFACTURING:

We have acquired new equipment for use at the manufacturing facility located in Washington State where the company’s products are made. This allows the Company to roll out an entire new line of supplements and varieties of other products. This equipment has arrived at the location and installation is in progress. This equipment will help us to control and expand the manufacturing process in order to increase our efficiency and delivery levels.

The latest equipment includes:

1.  NJP-800 Automatic Capsule Filling Machine – Makes 48,000 dry capsules per hour and is GMP approved. Products: Hard Capsules, allow any dry supplement blend that we create to be encapsulated.

2.  ZP-9 Rotary Tablet Press – Makes 12,000 tablets per hour and is GMP approved. Products: Dab Tablets, Pet Tablets, Coated Ibuprofen type tablets, hard press items like Lifesavers.

3.  2M Conveyor Belt Line – Increases bottling and labeling process by 25%

4.  Small Capsule Counter ZN-400 – Counts/Fills 1,800 bottles of Capsules per hour. Fills capsule bottles with precision for faster filling/sealing of hard capsules and dry tablets.

5.  Additional Die Set for ZP-9 Tablet Press – Allows 'CANB' embossment for the Ibuprofen type coated dry tablets.

6.  YD-2 Tablet Tester – Quality Control equipment that determines optimum levels for dry tablets and Dab Tablets during production.

7.  BY-400 Coating Machine – Coatings for dry tablets made by the ZP-9 machine to give Enteric coatings, buffers, and color to the pressed hard tablets.

8.  DPT-80 Blister Pack Machine – Makes 1,800 units per hour. Setup for 6 or 8 sizes #0 dry capsules made with the NJP-8 machine, and allows us to pack the capsules in easy to tear flat-packs with a thin box for shelves; will allow us to present our products in smaller amounts like Tylenol cold medicine liquid-gels, Sudafed etc.

9.  DCJ Liquid Sachet Packing Machine – Makes 3,600 unites per hour. The machine makes liquid packs of our items, such as freeze-pops, freeze gel and lotion samples, tincture samples and other liquid products we produce.

10.  DCF Powder Sachet Packing Machine – Makes 3,600 units per hour. The machine makes dry packs of our items, such as retail-ready water-soluble powder for drink mixes, coffee, tea smoothies, etc., in sugar-packet sizes.

11.  SL-130 Automatic Labeling Machine – Rolls 6,000 labels per hour. Auto Date Code and Conveyor Setup. Machine speeds up labeling and allows us to use professional labels on all round products.

About Canbiola, Inc.

Canbiola, Inc. is a public company trading under symbol  CANB .

Canbiola, Inc. is a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola is in the process of developing its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states. The company has already launched several products found at  www.canbiola.com .

The company also owns two technological solutions, Wrapmail (US Patent 8,572,275), which turns traditional email into a powerful marketing and branding tool, as well Prosperity Systems and the Bullseye platform of document management and compliance targeted at broker-dealers, public companies, and governmental agencies providing a flawless all-in-one solution for document management, retention and compliance.

Forward-looking statements and risks and uncertainties Matters discussed in this press release contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.

Follow us on  Twitter  and  Facebook

CONTACT:

Canbiola Investor Relations

Email: IR@canbiola.com

Phone: (516) 595-9544

http://www.canbiola.com

 

 

News Provided by GlobeNewswire via QuoteMedia

CEO and Medical Adviser of Canbiola, Inc., Discuss Company Updates with Everett Jolly on Uptick Newswire’s “Stock Day” Podcast

 

Phoenix, AZ (August 7, 2018) – Canbiola (OTC: CANB) (the “Company”) announced CEO Marco Alfonsi and medical adviser, Dr. Bob Kornfeld’s interview on Uptick Newswire’s “Stock Day” Podcast.

 

Jolly began the interview by asking CEO Marco Alfonsi for an update on the company since last appearing on the show on June 6, 2018.

 

Alfonsi stated that Canbiola is a CBD company that deals with a 99.5% or higher pure isolate. The Company works with at least 100 doctor’s offices at this point with a very high success rate and are experiencing continued and rapid growth.

 

Alfonsi briefly mentioned the shareholder’s letter from mid-July, which indicated that Canbiola continues to engage strategic medical partners that have allowed the Company to penetrate new markets and exponentially grow its exposure. This has involved the training of sales teams, which has begun to show results.

 

Alfonsi indicated that Canbiola doubled revenues from its 1 st quarter in its second quarter. He plans to expand the Company’s product line by the 4 th quarter 2018.

 

Jolly wanted to know, “How is Canbiola changing patients’ lives?”

 

Dr. Kornfeld indicated that in his practice, its use has made a huge difference and he thinks it will certainly make a difference in the delivery of pain medicine. The physician seeks to find out why the immune system is struggling to heal. “It all comes down to a very, very important process that happens in the human body to keep us healthy and it’s called homeostasis.” What that really means is that doctors are not only relieving pain and inflammation, but patients now have more efficient homeostasis. Doctors are doing this without drugs and side effects, while pushing the body to actually be healthier. Dr. Kornfeld feels this is really the future of medicine.

 

Jolly asked Alfonsi, “Where do you see the Company 12 months from now?”

 

Alfonsi indicated he is very optimistic that he can continue to help expand the size of the third party manufacturing facility where Canbiola’s products are made, exclusively, to help meet growing demand. “The results speak for themselves. The product is being accepted. The doctors are now starting to refer more physicians to us. So, when you have physicians referring other physicians, we’re obviously on the right path.”

 

Jolly ended the interview by asking if either gentleman wanted to add something else. Dr. Kornfeld said he wanted to add that physicians need to be educated to become aware of safer alternatives to drugs. Canbiola is in a position to really break open the whole movement away from drugs that cause addiction or death by overdose toward a product that is all natural. He said, “This is a really exciting time to be in this industry.”

For more information about the Company’s financial details, listen to the full interview at the link below:

 

https://upticknewswire.com/featured-interview-ceo-marco-alfonsi-of-canbiola-inc-otcpink-canb/

 

About CANB

Canbiola, Inc., is a U.S. Company specializing in the sale of a variety of Cannabidiol (CBD) based products such as oils, creams, moisturizers, chews, vapes, isolate, gel caps, concentrate and water. Canbiola is developing their own line of proprietary products, as well as seeking synergistic value through acquisitions in the CBD and Legal Medical Marijuana Industry. Canbiola is committed to providing the highest quality and lowest cost hemp solutions with the highest purity standards in the industry. Canbiola and its employees are passionate about improving people's lives. We take pride in providing pure products infused with organic and natural ingredients. When purchasing our products, we want customers to know that they are buying lab tested, high quality natural products at a great price. Cannabis derived products, including CBD, are considered federally illegal. Canbiola aims to operate legally in the states that have enacted cannabis or CBD regulations. The Company also owns two technological solutions: (1) WrapMail (US patent 8,572,275), which turns regular emails into marketing and branding for the sender; and (2) Prosperity/Bullseye, which is a solution for document management and compliance targeted at broker dealer, public companies and governmental agencies, requiring a flawless all-in-one solution for document management, retention and compliance.

 

Contact:

Canbiola

960 South Broadway

Suite 120

Hicksville, NY 11801

516-205-4751

https://canbiola.com/

info@canbiola.com

 

Safe Harbor Act and Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company’s most recent filings with the

Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

 

About Uptick Newswire and the “Stock Day” Podcast

Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.

 

Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/

 

# # #